$LAB News

Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale - Slideshow

Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools To Merge With Treeline Bioscience In All-Stock Transaction That Values LAB At Estimated $460M; Combined Company Expected To Operate As Treeline Biosciences And Trade On Nasdaq Under Symbol 'TRLN'

Standard BioTools Inc (NASDAQ:LAB) Shares Rise After Q1 Earnings Beat

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $81.504M Est

Standard BioTools Q1 EPS $(0.04) Beats $(0.06) Estimate, Sales $21.146M Beat $17.914M Estimate

Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why

Labrador Gold Welcomes Recent Announcement by the Ontario Government Concerning Accelerated Development of the Ring of Fire Road

Labrador Gold Announces Closing of Change of Business and Acquisition of Units of Northern Shield

CORRECTION – Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders

Labrador Gold Announces Voting Results of the 2026

Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders

Standard BioTools Inc (NASDAQ:LAB) Surges on Strong Q4 Earnings Beat

Standard BioTools: Q4 Earnings Snapshot

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Standard BioTools shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Standard BioTools Q4 Earnings Report: What Investors Need to Know